[ad_1]
(CercleFinance.com) – Merck today announced the results of the phase 3 trial (KEYNOTE-811) evaluating Keytruda in combination with trastuzumab, fluoropyrimidine and platinum chemotherapy, for the first-line treatment of patients with locally advanced, unresectable or metastatic, HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
‘These data highlight the importance of Keytruda, in combination with trastuzumab and chemotherapy, as a treatment option for patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma […] and reinforce our commitment to continuing to explore effective therapies for difficult-to-treat gastrointestinal cancers,’ commented Dr. Yelena Y. Janjigian, attending physician-in-chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center.
These data are being presented today in a communications session at the European Society for Medical Oncology (ESMO) 2023 Congress and are being discussed with regulatory authorities around the world.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
[ad_2]
Source link -85